ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Effects of Diacylglycerol Oil on Overweight or Obese Patients with Diabetes or Prediabetes: a Single-Arm Trial.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The annual incidence of overweight or obesity and abnormally elevated blood glucose levels in China is increasing. According to research, diacylglycerol oil offers effective lipid-lowering and weight-loss properties. This study aimed to elucidate the effects of diacylglycerol oil on overweight and obese patients with unusually high blood glucose levels. Methods: This is a single-arm trial. A total of 75 overweight or obese subjects with abnormally elevated blood glucose levels were included in this study. Subjects were requested to use diacylglycerol oil to cook food daily for two months and to maintain their daily eating habits and drug treatment regimen. Study-related parameters were assessed, respectively, during the screening period, one month, and two months following DAG oil consumed. Results: Fasting blood glucose (FBG), body weight, body mass index (BMI), waist circumference, and hip circumference decreased compared with baseline after consuming diacylglycerol oil for two months. FBG and glycosylated hemoglobin (HbAlc) levels decreased in prediabetic subjects (FBG decreased at visit 2 months: -0.31 mmol/l; at visit 1 month: -0.28 mmol/l; HbAlc decreased at visit 2: -0.10%; Conclusion: Diacylglycerol oil may help to prevent diabetes and delays its progression in overweight or obese patients. Clinical Trial Registry: ChiCTR2000028888 at www.chictr.org.cn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.